The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.
The LLSC pleased to partner with the Cancer Research Society (CRS) to fund ten (10) Operating Grants this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.
The LLSC is pleased to announce a research funding partnership with Waldenstrom’s Macroglobulemia Foundation of Canada to fund one (1) grant in this competition. The Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC) supports Canadians with WM, and their families, by offering a range of services that can enhance quality of life for those with WM and funding research to ultimately discover a cure. WM applications should address signaling, immunology/immunotherapy, tumor microenvironment, “Omics”, or IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).
New this year, the LLSC is pleased to announce a research funding partnership with Cell Therapy Transplantation Canada (CTTC) to fund one (1) grant in this competition. CTTC is a member-led, national, multidisciplinary organization providing leadership and promoting excellence in patient care, research and education in the field of hematopoietic cell transplant and cell therapy (HCT/CT). CTTC applications should describe an innovative multicentre project that aims to improve the outcome, efficacy, and/or safety of HCT/CT in Canada.
The LLSC is also pleased to announce a research funding partnership with Myeloma Canada to fund one (1) grant in this competition. Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. The organization is driven to improve the lives of those affected by myeloma by empowering the community through awareness, education and advocacy programs, and supporting clinical research to find a cure. Since it was founded in 2005, Myeloma Canada has been making myeloma matter. Applications relating to the treatment of multiple myeloma should aim to accelerate the development of Canadian academic cellular therapies.
How to apply
The application process will occur in two phases.
Phase Ⅰ - Submission and consideration of a Letter of Intent (LOI).
Phase ⅠⅠ - Invitation to submit a Full Application.
Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating system.
Key dates for 2023-2024
- Call for Proposals - September 18 2023
- Letter of Intent (LOI) due - October 26 2023, 4:00 pm (ET)
- Notification of Full Application Invite - November 2023
- Full application deadline - February 1 2024, 4:00 pm ET
- Review Panel Meeting - April 2024
- Notification of Awards - May 2024
- Award Start Date - July 2024
Read the guidelines
Applicants must carefully read the program guidelines before beginning their applications as application details have changed in 2023.
Submitting a letter of intent
Submitting a Letter of Intent is mandatory for all applicants.